AU2002226342A1 - Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis - Google Patents

Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis

Info

Publication number
AU2002226342A1
AU2002226342A1 AU2002226342A AU2634202A AU2002226342A1 AU 2002226342 A1 AU2002226342 A1 AU 2002226342A1 AU 2002226342 A AU2002226342 A AU 2002226342A AU 2634202 A AU2634202 A AU 2634202A AU 2002226342 A1 AU2002226342 A1 AU 2002226342A1
Authority
AU
Australia
Prior art keywords
gpiib
antibodies used
inhibiting angiogenesis
iiia antibodies
recombined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226342A
Other languages
English (en)
Inventor
Peter Berchtold
Robert Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASAT AG Applied Science and Technology
Original Assignee
ASAT AG Applied Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASAT AG Applied Science and Technology filed Critical ASAT AG Applied Science and Technology
Publication of AU2002226342A1 publication Critical patent/AU2002226342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002226342A 2000-11-20 2001-11-20 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis Abandoned AU2002226342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10057443.2 2000-11-20
DE10057443A DE10057443A1 (de) 2000-11-20 2000-11-20 Rekombinante Anti-GPIIB/IIIA-Antikörper als Mittel zur Hemmung der Angiogenese
PCT/EP2001/013445 WO2002040048A2 (de) 2000-11-20 2001-11-20 Rekombinante anti-gpiib/iiia-antikörper als mittel zur hemmung der angiogenese

Publications (1)

Publication Number Publication Date
AU2002226342A1 true AU2002226342A1 (en) 2002-05-27

Family

ID=7663917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226342A Abandoned AU2002226342A1 (en) 2000-11-20 2001-11-20 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis

Country Status (7)

Country Link
US (1) US20040022791A1 (de)
EP (1) EP1335746A2 (de)
JP (1) JP2004513927A (de)
AU (1) AU2002226342A1 (de)
CA (1) CA2428649A1 (de)
DE (1) DE10057443A1 (de)
WO (1) WO2002040048A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
WO2020237304A1 (en) * 2019-05-27 2020-12-03 Baker Heart and Diabetes Institute Antigen-binding molecules that bind the active conformation of platelet integrin receptor gpiib/iiia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0990034A1 (de) * 1997-06-06 2000-04-05 Asat AG Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
WO1999062549A1 (en) * 1998-06-04 1999-12-09 Mount Sinai School Of Medicine Of New York University Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases

Also Published As

Publication number Publication date
DE10057443A1 (de) 2002-05-23
WO2002040048A3 (de) 2002-08-01
CA2428649A1 (en) 2003-05-13
JP2004513927A (ja) 2004-05-13
WO2002040048A2 (de) 2002-05-23
US20040022791A1 (en) 2004-02-05
EP1335746A2 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
AU2001229395A1 (en) Microscope cover slip materials
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2002222112A1 (en) Hybrid antibodies
AU2001234125A1 (en) Antibody library
MXPA03008031A (es) Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
AU2001247417A1 (en) Cross-reactive sensors
AU2001237303A1 (en) Polysiloxanes used for hydrophobing
AU2002214033A1 (en) Actuating device
MXPA03000801A (es) Composicion de cemento disolvente en aerosol.
AU2001246934A1 (en) Agonist antibodies
AU2002230531A1 (en) Use of fgf-19 for inhibiting angiogenesis
AU2001276549A1 (en) Transglutaminase for inhibiting angiogenesis
AU143587S (en) Carton
AU2770601A (en) Compositions for enhancing the immune response
AU2002356180A1 (en) Methods for inhibiting angiogenesis
AU2002226342A1 (en) Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis
AU2001295582A1 (en) Tumour-related antigens
GB2367855B (en) Holding assembly for movable closure elememt
GB0104812D0 (en) Carton
AU2001245513A1 (en) Method for immune switching
AU4859301A (en) Antihistaminic compounds
AU2001245781A1 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU2001295042A1 (en) Anti-stilbene antibodies
AU2002216264A1 (en) High affinity antibodies
AU2002210775A1 (en) Convertible carton